WuXi Biologics has opened its new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
In April 2015 the firm announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city.
The first phase of construction is now complete and operations have begun.
The new facility accommodates two 1000L disposable bioreactors for perfusion processes and is the largest perfusion biologics manufacturing facility in Asia to implement disposable bioreactors.
The firm said this added capacity will support its biologics commercial manufacturing pipeline.
It will also address the needs of Chinese companies as a Marketing Authorisation Holder (MAH) system is currently being piloted.
'The opening of the new commercial manufacturing facility marks another milestone for WuXi,' said Dr. Ge Li, Chairman and CEO of WuXi AppTec.
'We will uphold the highest quality standards to expedite global development of biologics for both international and domestic clients.'
Dr Chris Chen, CEO of WuXi Biologics, said the new facility further strengthens WuXi Biologics' capabilities in integrated biologics discovery, development, and manufacturing services.
'WuXi Biologics is committed to providing a seamless, truly one-stop service for our partners and clients from concept to commercialisation,' he said.
